Compare SILO & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SILO | ICCM |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Apparel | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.6M |
| IPO Year | 2011 | 2013 |
| Metric | SILO | ICCM |
|---|---|---|
| Price | $1.35 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.67 |
| AVG Volume (30 Days) | 21.9K | ★ 113.1K |
| Earning Date | 11-16-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $72,102.00 | N/A |
| Revenue This Year | N/A | $27.11 |
| Revenue Next Year | N/A | $104.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $0.13 |
| 52 Week High | $10.43 | $9.54 |
| Indicator | SILO | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 18.44 |
| Support Level | $1.30 | $0.25 |
| Resistance Level | $1.38 | $2.50 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 81.10 | 10.97 |
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.